Alkermes earnings were $66.1M for the trailing 12 months ending Jun 30, 2026, with -81.3% growth year over year. The latest ALKS earnings report on Jun 30, 2026 announced Q2 2026 earnings of $501.0k, down 100.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ALKS reported annual earnings of $241.7M, with -34.2% growth.
ALKS past earnings growth
How has ALKS's earnings growth performed historically?
On ALKS's earnings call on Jul 28, 2026, Alkermes (NASDAQ: ALKS) reported Q2 2026 earnings per share (EPS) of $0.00, up 100% year over year. Total ALKS earnings for the quarter were $501.00 thousand. In the same quarter last year, Alkermes's earnings per share (EPS) was $0.53.
As of the last Alkermes earnings report, Alkermes is currently profitable. Alkermes's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $66.12 million, a 81.02% decrease year over year.
What was ALKS's earnings growth in the past year?
As of Alkermes's earnings date in Jul 28, 2026, Alkermes's earnings has grown -81.31% year over year. This is 89.42 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 8.11%. ALKS earnings in the past year totalled $66.12 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.